27 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases | ||
Programme de rachat - novembre 2012 (french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Forcyl® - a booming brand Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs. |
Public releases | ||
Programme de rachat - octobre 2012 (french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Sales momentum continues in Q3 Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year. |
Public releases | ||
Programme de rachat - septembre 2012(french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Vétoquinol purchases ORSCO laboratoire vétérinaire Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire. |
Public releases |